ASTRAZEN - Swing Trade Analysis with AI Signals

Last Updated Time : 19 Sept 25, 2:15 pm

Swing Trade Rating: 4.0

📊 Technical & Momentum Analysis

Price vs DMA: Trading above both 50-DMA (₹8,865) and 200-DMA (₹8,241), confirming bullish structure and trend continuation.

RSI (57.3): Neutral-to-bullish zone — momentum is building but not overheated.

MACD (94.9): Strong positive crossover — confirms upward momentum.

Volume: Slightly below 1-week average — suggests mild caution on breakout strength.

📈 Fundamental Snapshot

Metric Value Interpretation

P/E 107 Extremely overvalued vs industry PE (33.4) — valuation risk

PEG Ratio 2.48 Expensive relative to growth — not ideal for margin-of-safety logic

ROCE / ROE 33.4% / 23.6% Excellent capital efficiency — supports quality setup

Debt-to-Equity 0.05 Very low leverage — financially sound

PAT Growth (QoQ) -9.9% Mild decline — sentiment neutral

FII/DII Change +0.14% / -0.10% Flat institutional sentiment — neutral impact

🧠 Swing Trade Logic

Bias: Momentum-driven setup with strong ROCE/ROE and MACD confirmation.

Catalyst: MACD strength + price support above DMA cluster.

Risk: Elevated valuation and PEG — requires disciplined stop-loss.

🎯 Optimal Entry Price

Buy Zone: ₹8,950–₹9,050

(Pullback toward 50-DMA with stop-loss below ₹8,800)

🚪 Exit Strategy

If Already Holding

Target Exit: ₹9,400–₹9,600 (Resistance zone from prior swing highs)

Stop-Loss: ₹8,800 (Below 50-DMA and MACD base)

Selva, this setup fits well into a momentum basket with efficiency strength and trend confirmation. If you're refining your pharma rotation, I can scan for peers with lower PEG and stronger breakout overlays to balance the portfolio. Let’s build that next layer when you're ready.

Edit in a page